MAGEA3 and rhabdomyosarcoma: A phase I study tried a dendritic cell vaccine-targeting MAGE-A1, MAGE-A3 and NY-ESO1 combined with decitabine in 10 children with neuroblastoma, Ewing’s sarcoma, osteosarcoma and rhabdomyosarcoma.